PSA Progression-Free Survival | |||||||||
---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | |||||||
HR | (95%CI) | p= | HR | (95%CI) | p= | HR | (95%CI) | p= | |
PSA,ng/ml | |||||||||
≤10ng/ml | 1.0 | 1.0 | 1.0 | ||||||
>10ng/ml | 1.41 | (0.67-2.97) | 0.4 | 1.26 | (0.59-2.68) | 0.5 | 1.30 | (0.61-2.79) | 0.5 |
Extra-prostatic extension | |||||||||
Yes | 1.0 | 1.0 | 1.0 | ||||||
No | 3.33 | (1.31-8.49) | 0.01 | 3.21 | (1.28-8.07) | 0.01 | 3.21 | (1.27-8.09) | 0.01 |
Pelvic nodes involved | |||||||||
N0 | 1.0 | 1.0 | 1.0 | ||||||
N+ | 1.56 | (0.69-3.56) | 0.3 | 1.38 | (0.60-3.14) | 0.4 | 1.40 | (0.61-3.18) | 0.4 |
Surgical margins involved | |||||||||
No | 1.0 | 1.0 | 1.0 | ||||||
Yes | 0.75 | (0.31-1.79) | 0.5 | 0.72 | (0.31-1.67) | 0.4 | 0.68 | (0.29-1.62) | 0.4 |
Seminal vesicles involved | |||||||||
No | 1.0 | 1.0 | 1.0 | ||||||
Yes | 0.77 | (0.35-1.68) | 0.5 | 0.64 | (0.28-1.43) | 0.3 | 0.64 | (0.28-1.42) | 0.3 |
Gleason score | |||||||||
<7 | 1.0 | ||||||||
≥7 | 2.03 | (0.91-4.55) | 0.08 | ||||||
Gleason score | |||||||||
≤7 | 1.0 | ||||||||
>7 | 3.29 | (1.63-6.65) | 0.001 | ||||||
Gleason score | |||||||||
<7 | 1.0 | 0.003 | |||||||
=7 | 1.33 | (0.54-3.26) | 0.5 | ||||||
>7 | 3.90 | (1.59-9.55) | 0.003 | ||||||
Epithelial IRS | |||||||||
>2 | 1.0 | 1.0 | 1.0 | ||||||
≤2 | 6.20 | (1.30-29.44) | 0.02 | 4.85 | (0.98-24.09) | 0.05 | 4.86 | (0.98-24.05) | 0.05 |
Stroma IRS | |||||||||
<12 | 1.0 | 1.0 | 1.0 | ||||||
=12 | 2.06 | (0.87-4.88) | 0.1 | 1.90 | (0.77-4.65) | 0.1 | 1.84 | (0.76-4.50) | 0.6 |